Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Recordati, Positive

Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment of endogenous Cushing’s syndrome in adults.

28.07.2020 - 08:00:28

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology. Patients with Cushing’s disease, the most common form of endogenous Cushing’s syndrome, have an increased risk of significant comorbidities, including cardiovascular and cerebrovascular diseases as a result of excessive cortisol levels.1 Data from the large LINC-3 study, which enrolled 137 patients with Cushing’s disease, demonstrate that Isturisa® rapidly reduces mUFC and sustains this reduction alongside improvements in comorbidities, clinical signs and patients’ quality of life over 48 weeks.

and https://www.recordatirarediseases.com/ or follow us on LinkedIn or Twitter for company updates.

@ businesswire.com